Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists

References

• Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355: 2452–2466.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Silverstein MN. Treatment of polycythaemia vera andessential thrombocythaemia. Baillieres Clin Haematol 1998; 11: 769–785.
   PubMedGoogle Scholar
• Finazzi G, Harrison C. Essential thrombocythemia. Semin Hematol 2005; 42: 230–238.
   PubMed Web of Science ®Google Scholar
• Briere JB. Essential thrombocythemia. Orphanet J Rare Dis 2007;2: 3.
   PubMed Web of Science ®Google Scholar
• Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 2005; 29: 481–491.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythe-mia. Mayo Clin Proc 2001; 76: 22–28.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, BautersF. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549–556.
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G. Therapy for polycythemia vera and essentialthrombocythemia is driven by the cardiovascular risk. Semin Thromb Hemost 2007; 33: 321–329.
   PubMed Web of Science ®Google Scholar
• Elliott MA, Tefferi A. Thrombosis and haemorrhage in poly-cythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128: 275–290.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Barbui T. Risk-adapted therapy in essential thrombo-cythemia and polycythemia vera. Blood Rev 2005; 19: 243–252.
   PubMed Web of Science ®Google Scholar
• Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythe-mia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91: 616–622.
   PubMed Web of Science ®Google Scholar
• Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23: 132–143.
   PubMed Web of Science ®Google Scholar
• Najean Y, Rain JD, Dresch C, et al. Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias". Leuk Lymphoma 1996; 22(Suppl 1): 111–119.
   PubMedGoogle Scholar
• Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlor-ambucil therapy. N Engl J Med 1981; 304: 441–447.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency [Internet]: Xagrid, Summary of product characteristics February 2 2008. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Xagrid/H-480-PI-en.pdf (accessed June 27, 2008).
   Google Scholar
• Shire. Agrylino. Product information, 2007.
   Google Scholar
• Silverstein MN, Petitt RM, Solberg LA, Fleming JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988; 318: 1292–1294.
   PubMed Web of Science ®Google Scholar
• Anagrelide Study Group. Anagrelide, a therapy for thrombocythe-mic states: experience in 577 patients. Anagrelide Study Group. Am J Med 1992; 92: 69–76.
   PubMed Web of Science ®Google Scholar
• Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F, Mandelli F. Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results. Haematologica 1992; 77: 315–317.
   PubMed Web of Science ®Google Scholar
• Basara N, Gotic M, Bogdanovic A, Rolovic Z. Treatment of thrombocythemia with Anagrelide: a single institutional experi-ence. Eur J Clin Pharmacol 1997; 52: A103.
   Google Scholar
• Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control ofthrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 1997; 34: 51–54.
   PubMed Web of Science ®Google Scholar
• Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol 1998; 61: 71–76.
   PubMed Web of Science ®Google Scholar
• Mills AK, Taylor KM, Wright SJ, et al. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombo-cythaemia. Aust N Z J Med 1999; 29: 29–35.
   PubMedGoogle Scholar
• Laguna MS, Kornblihtt LI, Marta RF, Michiels JJ, Molinas FC. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin App/ Thromb Hemost 2000; 6: 157–161.
   PubMed Web of Science ®Google Scholar
• Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001; 97: 863–866.
   PubMed Web of Science ®Google Scholar
• Kornblihtt LI, Vassallu PS, Heller P, Molinas FC. Treatment of essential thrombocythemia with anagrelide: a ten-year experience. Medicina (B Aires) 2002; 62: 231–236.
   PubMed Web of Science ®Google Scholar
• Zomas A, Marinakis T, Grigoraki V, et al. The use anagrelide for control of thrombocytosis in Greek patients with myeloprolifera-tive disorders. Haem 2002; 5: 320–325.
   Google Scholar
• Birgegard G, Bjorkholm M, Kutti J, et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 2004; 89: 520–527.
   PubMed Web of Science ®Google Scholar
• Mazur G, Wrobel T, Podolak-Dawidziak M, et al. Anagrelide in the treatment of thrombocythemia essential (ET). Pol Arch Med Wewn 2004; 112: 1445–1450.
   PubMedGoogle Scholar
• Mazzucconi MG, Redi R, Bernasconi S, et al. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica 2004; 89: 1306–1313.
   PubMed Web of Science ®Google Scholar
• Penninga E, Jensen BA, Hansen PB, et al. Anagrelide treatment in 52 patients with chronic myeloproliferative diseases. Clin Lab Haematol 2004; 26: 335–340.
   PubMedGoogle Scholar
• Steurer M, Gastl G, Jedrzejczak WW, et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004; 101: 2239–2246.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33–45.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombo-cythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.
   PubMed Web of Science ®Google Scholar
• Antonioli E, Guglielmelli P, Poli G, et al. Influence of JAK2V617Fallele burden on phenotype in essential thrombocythemia. Haematologica 2008; 93: 41–48.
   PubMed Web of Science ®Google Scholar
• Hsiao HH, Yang MY, Liu YC, et al. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. Exp Hematol 2007; 35: 1704–1707.
   PubMed Web of Science ®Google Scholar
• Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007; 109: 2279–2284.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092–1097.
   PubMed Web of Science ®Google Scholar
• Lahuerta-Palacios ii, Bornstein R, Fernandez-Debora FJ, et al. Controlled and uncontrolled thrombocytosis. Its clinical role in essential thrombocythemia. Cancer 1988; 61: 1207–1212.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythe-mia. J Clin Oncol 1990; 8: 556–562.
   PubMed Web of Science ®Google Scholar
• Birgegard G. Essential thrombocythaemia treatment options: addressing patient-specific needs. Eur J Haematol Suppl 2007; 79: 27–31.
   Google Scholar
• Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89: 215–232.
   PubMed Web of Science ®Google Scholar
• Schwarz J, Pytlik R, Doubek M, et al. Analysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia. Semin Thromb Hemost 2006; 32: 231–245.
   PubMed Web of Science ®Google Scholar
• Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997; 90: 3370–3377.
   PubMed Web of Science ®Google Scholar
• Nand S, Stock W, Godwin J, Fisher SG. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombo-cythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol 1996; 52: 42–46.
   PubMed Web of Science ®Google Scholar
• Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol 2003; 74: 26–31.
   PubMed Web of Science ®Google Scholar
• Randi ML, Fabris F, Girolami A. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia. Leuk Lymphoma 2000; 37: 379–385.
   PubMed Web of Science ®Google Scholar
• Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydro-xyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeu-tic implications. Eur J Haematol 1994; 52: 134–139.
   PubMed Web of Science ®Google Scholar
• Birgegard G. Anagrelide treatment in myeloproliferative disorders. Semin Thromb Hemost 2006; 32: 260–266.
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Kralovics R, Gotic M, et al. Non-inferiority of anagrelide compared to hydroxyurea in newly diagnosed patients with essential thrombocythaemia: The ANAHYDRET study. 49th Annual Society of Hematology Annual Meeting, Atlanta, USA, 8–11 December 2007.
   Google Scholar
• Barosi G, Besses C, Birgegard G, et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential throm-bocythemia: results of a consensus process by an international working group. Leukemia 2007; 21: 277–280.
   PubMed Web of Science ®Google Scholar
• Reilly JT. Implications of the consensus definition of clinical resistance and intolerance to hydroxyurea for clinical practice. Eur J Haematol Suppl 2007; 79: 32–34.
   Google Scholar